PINE BROOK, N.J., July 30 /PRNewswire/ -- Elusys Therapeutics, Inc.
(Elusys), a privately-held biopharmaceutical company developing proprietary
Heteropoloymer (HP) Antibodies for the treatment of life-threatening
infectious diseases, today announced the appointment of Ron Eastman as
Chairman of the Board of Directors, succeeding William R. Miller. Mr.
Eastman is a Partner at Essex Woodlands Health Ventures. Mr. Miller, a
former Vice Chairman of Bristol-Myers Squibb, will remain on the Board as a
Director.
The company also announced that James P. Porter has been promoted to
Vice President of Development and Manufacturing, expanding the senior
executive management team.
Elizabeth Posillico, Ph.D., President and Chief Executive Officer of
Elusys, commented on the appointments, "I welcome Ron Eastman as the
company's new Chairman. Ron brings considerable pharmaceutical and biotech
experience to our Board and I look forward to working with him as we
advance our pipeline and product platform. I am also personally delighted
to announce Jim Porter's promotion to Vice President. Jim has played a
seminal role in the development of our HP Antibody technology and his
leadership is important to the success of our products in advanced clinical
development."
Dr. Posillico continued, "We are pleased that Bill Miller will remain
on the Board as he is a true pharmaceutical industry legend who has served
with distinction as Elusys' Chairman since the company's inception in
1998."
Mr. Eastman commented, "Essex Woodlands is Elusys' largest investor and
we know the company well. We also know that HP Antibodies could change the
way serious infectious diseases are treated and it is an honor to be
invited to join this exciting company as Chairman. I look forward to
working closely with the management team and the other Directors to help
guide Elusys into clinical development with its lead HP Antibody product,
ETI-211, for the treatment of methicillin resistant Staphylococcus aureus
(MRSA)."
Mr. Eastman has nearly 30 years of experience in the healthcare and
biopharmaceutical businesses. He began his career at American Cyanamid
Company (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing
various pharmaceutical products, divisions and subsidiaries in the U.S. and
overseas. Since then he has helped build and create successful exits for
three leading healthcare companies including Rinat Neuroscience, which was
acquired by Pfizer in 2006. Mr. Eastman earned his B.A. from Williams
College and his M.B.A. from Columbia University.
Mr. Porter has more than 25 years of experience in commercial
biopharmaceutical development. Prior to joining Elusys in 1999 as Director
of Product Development, he was Director, Product Materials Development for
Heska Corporation and previously served for ten years in the Hybridoma
Development Group at Genentech. Mr. Porter received his B.S. in chemistry
from the University of Florida and his M.S. in biochemistry from the
University of South Carolina.
About Elusys' HP Antibody(TM) Technology
HP Antibodies represent a new approach for the treatment of antibiotic
resistant infections distinct from traditional therapies. HP Antibodies
utilize natural immune system mechanisms to clear pathogens and provide a
means to develop novel drug candidates targeted against bacterial, viral
and fungal infections. By targeting a unique immune receptor, HP Antibodies
enhance a natural clearance mechanism and direct the rapid removal of
pathogens from the circulation to tissue macrophages.
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the
development of antibody-based therapeutics for the treatment of
life-threatening infectious disease. Current venture investors include
Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo
Ventures, MedImmune Ventures and Pfizer. For more information please visit
http://www.elusys.com.
SOURCE Elusys Therapeutics, Inc.
 back to top
Related links:
http://www.elusys.com
CONTACT:
Martin Reynolds of LaVoie Group,
+1-978-745-4200, ext. 107, mreynolds@lavoiegroup.com, for Elusys
Therapeutics, Inc.
|
